Generic Competition 2007 to 2011

“The period 2007 to 2011 will see the expiration of patent protection for 52 major drugs in the United States, an average of ten a year. With 2005 seeing a decline in the number of NCEs approved down to 18 from 23 in 2004, there is clear evidence that the loss of revenue from patent protected drugs will impact upon the growth of the industry when so few new drugs are reaching the market.“

New generics in the period 2007 to 2011 threaten $100 billion of revenues generated in the United States and Europe. The most dramatic change in this period will arise in the period 2010 to 2012 as the patents covering Lipitor expire.

The loss of revenues to generic substitutes is a major influence on the financial performance of ethical R&D companies. Conversely the successful identification and exploitation of the opportunities afforded by patent expirations provides a major growth driver for the pharmaceutical companies who focus their business on the provision of generic therapeutics.

Generic Competition 2007 to 2011: The impact of patent expiries on sales of major drugs is a 50,000 word report that provides the valuable market data and insight that both ethical and generic pharmaceutical companies will find useful in their business.

This unique report will describe in detail which major selling drugs will be affected by patent expiry and the likely financial effect on the producer company. The following information for each drug is provided:

- Indication

- Manufacturer

- Revenues ($m) for 2001–06 (total and US)

- % of company’s 2005 revenues

- Share of market segment

- Key competitors

- Patent Status in US, France, Germany, Italy and UK

- Patenting activity by generics companies

- Generic regulatory filing activity

- Pending litigation issues

- Share of market segment

- Impact of generic substitutes:

Directly on distributor

Indirectly on competitors

On market segment

Distributor(s)

Franchise defence strategies

Key features of this report

Reviews of over 50 major drugs that will come off patent between 2007 and 2011

Listing of generic regulatory filing activity

Solid overview of market for generic drugs over the next four years

Global product sales figures for years 2001-2005 with share by company revenue & market segment

Use this report to:

Forecast the market share that will be lost to generic competition

Understand which global companies are under pressure from generics

Consider the effect of expiry on the patent holder’s competitors

See whether there are any outstanding litigation issues

Learn which generic companies are active in filing

Publication date February 2007

Pages 130 Format PDF
Table of Contents
Price: $2,845.00 / GBP1,422.50